Compare Abeona Therapeutics Inc (ABEO) vs iShares S&P GSCI Commodity-Indexed Trust ETF (GSG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs iShares S&P GSCI Commodity-Indexed Trust ETF — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while iShares S&P GSCI Commodity-Indexed Trust ETF trades at $32.61. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, iShares S&P GSCI Commodity-Indexed Trust ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | GSG | |
|---|---|---|
Market Cap | $421.19M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $7.45 | $34.77 |
52-Week Low | $4.17 | $22.06 |
Enterprise Value | $276.10M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
GSG, the iShares S&P GSCI Commodity-Indexed Trust ETF, trades at $32.62, up 0.93% on the day, with technical indicators showing a bearish bias from moving averages but neutral oscillators. The ETF's performance is heavily tied to energy commodities, which drove strong gains in H1 2026, though recent analyst sentiment has turned cautious due to sector volatility. Key support is at $31, with resistance at $32.
The outlook for GSG hinges on commodity market dynamics, particularly energy prices, offering exposure to broad commodities but facing risks from geopolitical tensions and volatility. Investor caution is warranted as analysts highlight increased risks near current price levels, with a recent downgrade to Hold reflecting concerns over sustained outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About iShares S&P GSCI Commodity-Indexed Trust ETF
GSG is a diversified commodity ETF that tracks the S&P GSCI Total Return Index. It provides exposure to a broad basket of futures, including energy, metals, and agriculture, with a significant weighting toward the energy sector.
Read more on GSG →
